Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 28, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 32,910	$ 41,582
Accounts receivable, net	132,367	127,393
Inventory	96,465	92,475
Prepaid and other current assets	13,461	14,160
Total current assets	275,203	275,610
Property and equipment, net	24,512	27,012
Goodwill	7,462	7,462
Intangible assets, net	386,954	404,729
Operating lease assets	6,225	6,506
Deferred tax assets	4,745	4,745
Investment and other assets	1,687	1,892
Total assets	706,788	727,956
Current liabilities:
Accounts payable	24,245	23,690
Accrued liabilities	113,666	135,879
Current portion of long-term debt	43,358	27,339
Current portion of contingent consideration	0	19,573
Other current liabilities	4,411	3,917
Total current liabilities	185,680	210,398
Long-term debt, less current portion	297,880	308,288
Deferred income tax liabilities	651	564
Other long-term liabilities	21,278	23,102
Total liabilities	505,489	542,352
Commitments and contingencies (Note 10)
Stockholders’ Equity
Additional paid-in capital	514,772	508,092
Accumulated deficit	(352,839)	(357,661)
Accumulated other comprehensive loss	(774)	(2,573)
Total stockholders’ equity attributable to Bioventus Inc.	161,242	147,940
Noncontrolling interest	40,057	37,664
Total stockholders’ equity	201,299	185,604
Total liabilities and stockholders’ equity	706,788	727,956
Common Class A
Stockholders’ Equity
Common stock, value	67	66
Common Class B
Stockholders’ Equity
Common stock, value	$ 16	$ 16